ELN -- president of the company said in an interview with the London Times published today ... "IT IS INCONCEIVABLE" (his words not mine) that the FDA will not approve re-introduction of tysabri because in his opinion the data provided for resubmittal was much better than the original data upon which the FDA had previously granted approval of tysabri --- maybe that accounts for the run-up today
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.